|Brown University, PhD|
Dale Pfost joined Advent in 2010. He has more than 25 years of experience as a life science entrepreneur and executive, with expertise in high technology research tools, genomics, diagnostics and therapeutics.
Daleâ€™s first company, founded while he was in graduate school, was acquired by SmithKline Beckman. He was founding CEO and Chairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine that Dale and his team built through strategic acquisitions and took public in 2000 (NASDAQ: ORCH). Dale then became founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company that was acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale readied the company for a successful acquisition by a European biotechnology firm. Earlier in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE).